Otero Jose Manuel
Known title: Chief Operating OfficerCIK: 0002024096
Associated companies
Transaction History
| LXEO | ▲ Buy | Grant | 2,110 | $6K | 9/14/2026 | View on chart |
| LXEO | ▼ Sell | Open Market | 1,304 | $6K | 8/18/2026 | View on chart |
| LXEO | ▼ Sell | Open Market | 4,666 | $21K | 7/1/2026 | View on chart |
| LXEO | ▲ Buy | Grant | 12,060 | $0 | 6/29/2026 | View on chart |
| LXEO | ▼ Sell | Open Market | 1,302 | $7K | 5/18/2026 | View on chart |
| LXEO | ▲ Buy | Grant | 5,930 | $16K | 3/13/2026 | View on chart |
| LXEO | ▼ Sell | Open Market | 3,016 | $19K | 2/18/2026 | View on chart |
| LXEO | ▲ Buy | Grant | 65,000 | $0 | 2/4/2026 | View on chart |
| LXEO | ▼ Sell | Open Market | 2,091 | $19K | 10/17/2025 | View on chart |
| LXEO | ▼ Sell | Open Market | 24 | $229 | 10/17/2025 | View on chart |
| LXEO | ▲ Buy | Grant | 5,940 | $0 | 10/15/2025 | View on chart |
| LXEO | ▼ Sell | Open Market | 721 | $7K | 8/18/2025 | View on chart |
| LXEO | ▼ Sell | Open Market | 2,848 | $13K | 8/18/2025 | View on chart |
| LXEO | ▲ Buy | Grant | 5,720 | $15K | 3/14/2025 | View on chart |
| LXEO | ▲ Buy | Grant | 26,250 | $0 | 1/7/2025 | View on chart |
| LXEO | ▲ Buy | Grant | 31,250 | $0 | 6/12/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
LXEO to Acquire Mantle Therapeutics, Expand Friedreich Ataxia Programs
Lexeo Therapeutics announced an agreement to acquire Mantle Therapeutics and enter new collaborations to expand its Friedreich Ataxia portfolio. The company also secured access to Apertura’s TfR1 CapX technology for its treatment programs. These strategic moves aim to strengthen Lexeo's position in the rare disease space, though the stock remains in a technical downtrend.
LXEO to Acquire Mantle Therapeutics, Expand Friedreich Ataxia Programs. Lexeo Therapeutics announced an agreement to acquire Mantle Therapeutics and enter new collaborations to expand its Friedreich Ataxia portfolio. The company also secured access to Apertura’s TfR1 CapX technology for its treatment programs. These strategic moves aim to strengthen Lexeo's position in the rare disease space, though the stock remains in a technical downtrend.